Total Return chart SynAct Pharma AB

Stocks

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-07-16 EDT			5-day change	1st Jan Change
19.60 ^SEK	+0.41%		-8.20%	-13.27%

07-09	Synact Pharma presents preclinical osteoarthritis data for resomelagon, shares rise	FW
07-09	Synact Pharma: Early preclinical results show resomelagon reduces osteoarthritis-related inflammation and joint damage	FW

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.